Axsome Therapeutics, Inc. (AXSM) has a negative trailing P/E of -47.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 29.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.09%, forward earnings yield 3.42%. PEG 0.47 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.8 | -0.08 | 5.99 | 0.00 | - |
| 2017 | -4.4 | 0.42 | 7.63 | 0.00 | - |
| 2018 | -2.4 | 0.26 | 80.83 | 0.00 | - |
| 2019 | -51.4 | -0.66 | 19.67 | 0.00 | - |
| 2020 | -29.5 | -0.77 | 26.64 | 0.00 | - |
| 2021 | -10.9 | -0.48 | 90.93 | 0.00 | - |
| 2022 | -16.8 | -0.51 | 28.62 | 62.67 | - |
| 2023 | -15.1 | -1.04 | 18.93 | 13.36 | - |
| 2024 | -14.1 | -1.03 | 71.10 | 10.51 | - |
| 2025 | -49.6 | 1.29 | 102.90 | 14.23 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.42 | $0.00 | $-27.2M | - |
| 2017 | $-1.27 | $0.00 | $-28.94M | - |
| 2018 | $-1.15 | $0.00 | $-30.97M | - |
| 2019 | $-2.05 | $0.00 | $-69.69M | - |
| 2020 | $-2.83 | $0.00 | $-105.39M | - |
| 2021 | $-3.59 | $0.00 | $-134.94M | - |
| 2022 | $-4.86 | $50.04M | $-197.77M | -395.2% |
| 2023 | $-5.27 | $270.6M | $-239.24M | -88.4% |
| 2024 | $-5.99 | $385.69M | $-287.22M | -74.5% |
| 2025 | $-3.68 | $638.5M | $-183.17M | -28.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.81 | $-3.87 – $0.89 | $987.95M | $917.41M – $1.07B | 13 |
| 2027 | $6.28 | $-1.76 – $13.27 | $1.54B | $1.18B – $1.88B | 12 |
| 2028 | $13.63 | $1.27 – $29.62 | $2.12B | $2.11B – $2.13B | 13 |
| 2029 | $21.61 | $17.02 – $27.11 | $2.79B | $2.34B – $3.34B | 11 |
| 2030 | $26.96 | $21.24 – $33.83 | $3.3B | $2.76B – $3.94B | 5 |
